GenprexNASDAQ: GNPX

License includes Genprex's Reqorsa® Gene Therapy in Combination with ALK-Inhibitors for the  Potential Treatment of ALK-Positive Lung Cancer AUSTIN, Texas , Nov. 20, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, exclusive license to the University's patent rights relating toits lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in combination with ALK-inhibitors for the potential treatment of ALK-EML4 positive translocated lung cancer. "We continue to bolster our intellectual property portfolio for REQORSA, understanding that our lead drug candidate may benefit patients with many types of cancers," said Thomas Gallagher, Esq.

REQORSA Modulates In Vivo Immune Responses Against Cancers AUSTIN, Texas , Nov. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at Meharry Medical College will present a poster detailing positive preclinical data from a study of the Company's lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid) evaluating TUSC2's role in modulating immune responses in cancer. The poster will be presented at the 39th Annual Society for Immunotherapy of Cancer Meeting being held November 6-10, 2024 in Houston, Texas.

Preclinical Data Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics AUSTIN, Texas , Oct. 28, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that research collaborators delivered poster presentations at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held October 23-25, 2024 in Barcelona, Spain. The collaborators presented posters on positive preclinical data from studies of Genprex's lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma.

Demonstrated Favorable Safety Profile of REQORSA AUSTIN, Texas , Oct. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the 0.09 mg/kg dose group of the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC). In addition, the Safety Review Committee (SRC) has approved escalation to the highest dose group of 0.12 mg/kg.

Reqorsa® Gene Therapy Overcomes Acquired Resistance to Lumakras® in Lung Cancer REQORSA Demonstrated Potent Tumor Suppressive Activity in Mesothelioma REQORSA Induces Apoptosis in Glioblastoma AUSTIN, Texas , Oct. 10, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024 in Barcelona, Spain. The collaborators will present posters on positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma.

Company's CEO and CFO Highlights its Cutting-Edge Gene Therapy Programs AUSTIN, Texas , Sept. 23, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, was featured in CEO/CFO Magazine discussing the Company's novel gene therapies for cancer and diabetes.

Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in Mesothelioma AUSTIN, Texas , Sept. 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Mesothelioma Clinical Advisory Board to support the Company's preclinical mesothelioma oncology program.

Intends to Create Two Distinct Businesses, Re-Focusing Genprex on its Oncology Clinical Development Program New Subsidiary to Focus on Developing Novel Gene Therapy for Diabetes AUSTIN, Texas , Sept. 4, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo").

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 3, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in September 2024.